Top executives weigh in at CIIE (V)

A1: This is the second time for Cytiva to participate in the CIIE after joining Danaher.

CIIE is an important platform for global companies to present their most innovative products and solutions to the China market, and a great opportunity to connect and communicate with customers, partners, media, government, and the public.

At this year's CIIE, we exhibit a series of innovative products and solutions and cooperate with several industry companies to facilitate the efficient development of China's biomedical industry and serve patients in China and around the world.

A2: We believe CIIE plays a significant role for global companies in demonstrating their most innovative products and relevant solutions to the China market, which also is a platform for exhibitors to explore opportunities of teaming up with trading partners across countries. It also shows China's advocacy for openness and cooperation in the world economy.

A3: Imports are a crucial bridge that connects domestic and international circulations, and an important channel for the world to explore the Chinese market.

We are supportive and wish to introduce more of our high-quality products from overseas to the Chinese market which could better advance and accelerate therapeutics.

China is one of Cytiva's most important and fastest-growing markets. With deep roots and heritage in this country, Cytiva will continue to accelerate and advance therapeutics with our know-how and technical innovation. The collaboration with our local partners displays our long-term commitment to the Chinese market and shows how our 'In China for China' strategy could also benefit the broader Asia-Pacific region.

A4: China is the second largest pharmaceutical market in the world, and the government has laid out a roadmap to transform healthcare by 2030 to meet the needs of its population.

Cytiva is a trusted collaborator for both academia and industry, which has a strong sense of purpose and is committed to growing its business sustainably to support the priorities of the Healthy China 2030 Agenda.

The biopharma industry is at the forefront of providing new solutions and accelerating the development of novel therapies that have the potential to transform human health.

A5: Benefiting from the opening-up policy, boosting the economy and increasingly growing the consumer market, we have expanded our business over the years, and built up a strong market position with several well-known brands that consumers trust and experts recommend.

With over 100,000 systems in use globally and 75 percent of FDA-approved biotherapeutics manufactured using our technologies, our leading brands are helping customers advance and accelerate therapeutics.

A6: In recent years, China has continuously deepened the reform and opening-up of the foreign investment management system, creating a fair, transparent and predictable business environment, which also demonstrates China's determination to promote a higher level of opening-up and further promote the development of the global economy.

Enterprises can also better seize the 'China Opportunities', activate new investment and economic vitality, creating soils for the growth of the industry.

A7: From CIIE and other platforms of opening up, we see the Chinese government's continued support to foreign companies in exploring business opportunities in China. We look forward to more policy support in cross-border e-commerce and other new business forms and models to facilitate the introduction of high-quality overseas products to China.

At the same time, as a global provider of technologies and services, Cytiva also leverages on its advantages in the field of biopharmaceutical to bring efficiencies to research and manufacturing workflows, ensuring the development, manufacture and delivery of transformative medicines to patients.

A8: The Chinese government has been continuing to make efforts in improving its business environment for foreign trade and foreign investment. From the Belt and Road Initiative to the CIIE, China has continuously expanded its opening-up, promoted the liberalization of trade and investment, helping foreign enterprises to better seize the opportunities in the Chinese market.